Ghada Ismail
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ghada Ismail has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Marwa Salah Mostafa
Department of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications - Nashwa Naguib Omar
Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 shared publications - Noha Alaa Eldin Fahim
Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 shared publications - Ahmed Elshafei
Urology Department, Faculty of Medicine, Modern University for Information and Technology, Cairo, Egypt
1 shared publication - Ahmed Mohamed Kamal Elshafei
Universit´e PSL
1 shared publication Amira Mohamed Mokhtar
Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 3 September 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 27778
Genomic and phenotypic characterization of Klebsiella pneumoniae phage KP Ø1: a novel lytic Slopekvirus targeting uropathogenic multidrug-resistant Klebsiella pneumoniae
The rise of multidrug-resistant (MDR) uropathogenic gram-negative bacteria (GNB) necessitates the development of alternative therapeutic strategies. This study aimed to isolate, phenotypically characterize, and perform whole-genome sequencing of the bacteriophage demonstrating the broadest host range against MDR uropathogens. Fifty MDR GNB isolates were screened for lytic phages. The most promising candidate, Klebsiella pneumoniae phage KP Ø1, was characterized using plaque assay, Transmission Electron Microscopy (TEM), and pH/thermal stability testing. Genomic characterization was performed via whole-genome sequencing (WGS), with functional annotation and lifestyle prediction using PhaBOX and PhageScope software. Klebsiella pneumoniae was the most prevalent MDR uropathogen. Klebsiella pneumoniae phage KP Ø1 exhibited a 50% host range and high lytic titer (10⁸ PFU/mL). TEM revealed an icosahedral head and short contractile tail. Genomic characterization by WGS revealed that Klebsiella pneumoniae phage KP Ø1 possesses a 174,591 bp double-stranded deoxyribonucleic acid (dsDNA) genome containing 274 predicted open reading frames (ORFs). No lysogeny-related genes, toxins, or antibiotic resistance markers were detected, confirming its strictly lytic nature and supporting its potential as a candidate for phage therapy applications. The phage remained stable (10⁸ PFU/mL) across temperatures of − 20 °C to 50 °C; supporting its suitability for long-term biobanking and suggesting potential activity at physiological temperature, and across a pH range of 7–9. Klebsiella pneumoniae phage KP Ø1 is a novel, obligately lytic Slopekvirus whose genomic architecture, stability profile, and absence of lysogeny-associated, virulence, and antimicrobial resistance genes ( AMR) collectively support its candidacy for further preclinical evaluation as a phage therapy agent against uropathogenic MDR Klebsiella pneumoniae .
- 3 September 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 27778
Open AccessGenomic and phenotypic characterization of Klebsiella pneumoniae phage KP Ø1: a novel lytic Slopekvirus targeting uropathogenic multidrug-resistant Klebsiella pneumoniae
The rise of multidrug-resistant (MDR) uropathogenic gram-negative bacteria (GNB) necessitates the development of alternative therapeutic strategies. This study aimed to isolate, phenotypically characterize, and perform whole-genome sequencing of the bacteriophage demonstrating the broadest host range against MDR uropathogens. Fifty MDR GNB isolates were screened for lytic phages. The most promising candidate, Klebsiella pneumoniae phage KP Ø1, was characterized using plaque assay, Transmission Electron Microscopy (TEM), and pH/thermal stability testing. Genomic characterization was performed via whole-genome sequencing (WGS), with functional annotation and lifestyle prediction using PhaBOX and PhageScope software. Klebsiella pneumoniae was the most prevalent MDR uropathogen. Klebsiella pneumoniae phage KP Ø1 exhibited a 50% host range and high lytic titer (10⁸ PFU/mL). TEM revealed an icosahedral head and short contractile tail. Genomic characterization by WGS revealed that Klebsiella pneumoniae phage KP Ø1 possesses a 174,591 bp double-stranded deoxyribonucleic acid (dsDNA) genome containing 274 predicted open reading frames (ORFs). No lysogeny-related genes, toxins, or antibiotic resistance markers were detected, confirming its strictly lytic nature and supporting its potential as a candidate for phage therapy applications. The phage remained stable (10⁸ PFU/mL) across temperatures of − 20 °C to 50 °C; supporting its suitability for long-term biobanking and suggesting potential activity at physiological temperature, and across a pH range of 7–9. Klebsiella pneumoniae phage KP Ø1 is a novel, obligately lytic Slopekvirus whose genomic architecture, stability profile, and absence of lysogeny-associated, virulence, and antimicrobial resistance genes ( AMR) collectively support its candidacy for further preclinical evaluation as a phage therapy agent against uropathogenic MDR Klebsiella pneumoniae .
- Open Access
- 2 January 2023
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 11 (A) , 122-126
The Impact of Sputnik SARS-CoV-2 Vaccines on Antibody Response in the Egyptian Population
BACKGROUND: The coronavirus disease 2019 (COVID-2019) causes the severe contagious acute respiratory syndrome. Therefore, massive vaccination campaign is mandatory to control the spread. Sputnik COVID-19 vaccines induce immunity through different mechanisms involving antibody response that bind to the spike protein to neutralize the viral entry into the cells. AIM: This study aims to compare the titers of specific antibodies in the pre- and post-vaccination sera in the vaccinated Egyptian population to evaluate the efficacy of the sputnik vaccine. METHODS: Samples were collected from 205 adult volunteers receiving the Sputnik vaccine in the Reference Laboratory of Egyptian University Hospitals. Samples were collected before vaccination and within 1, 2, or 3 months after receiving two doses of Sputnik SARS-CoV-2 vaccines from August to October 2021, serum samples collected were tested by quantitative chemiluminescent immunoassay using (Mindray CL-960i chemiluminescence analyzer, India) at the Reference laboratory of Egyptian University Hospitals for neutralizing antibodies, anti-spike antibodies, and total antibody levels before and after vaccination. RESULTS: The results of the 205 paired samples illustrated that there was a statistically significant difference between pre- and post-vaccination antibody levels with a p-value of (< 0.001) indicating that the vaccine produced significantly high levels of antibodies. CONCLUSION: COVID-19 Sputnik vaccines induce immunity through an antibody response that binds to the virus to neutralize its entry into cells. Our study showed a significant increase in the measured post-vaccination levels of the three antibodies among the enrolled volunteers compared to the basal pre-vaccination level and thus sputnik vaccine protects against SARS-CoV-2 infections.
- 2 January 2023
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 11 (A) , 122-126
Open AccessThe Impact of Sputnik SARS-CoV-2 Vaccines on Antibody Response in the Egyptian Population
BACKGROUND: The coronavirus disease 2019 (COVID-2019) causes the severe contagious acute respiratory syndrome. Therefore, massive vaccination campaign is mandatory to control the spread. Sputnik COVID-19 vaccines induce immunity through different mechanisms involving antibody response that bind to the spike protein to neutralize the viral entry into the cells. AIM: This study aims to compare the titers of specific antibodies in the pre- and post-vaccination sera in the vaccinated Egyptian population to evaluate the efficacy of the sputnik vaccine. METHODS: Samples were collected from 205 adult volunteers receiving the Sputnik vaccine in the Reference Laboratory of Egyptian University Hospitals. Samples were collected before vaccination and within 1, 2, or 3 months after receiving two doses of Sputnik SARS-CoV-2 vaccines from August to October 2021, serum samples collected were tested by quantitative chemiluminescent immunoassay using (Mindray CL-960i chemiluminescence analyzer, India) at the Reference laboratory of Egyptian University Hospitals for neutralizing antibodies, anti-spike antibodies, and total antibody levels before and after vaccination. RESULTS: The results of the 205 paired samples illustrated that there was a statistically significant difference between pre- and post-vaccination antibody levels with a p-value of (< 0.001) indicating that the vaccine produced significantly high levels of antibodies. CONCLUSION: COVID-19 Sputnik vaccines induce immunity through an antibody response that binds to the virus to neutralize its entry into cells. Our study showed a significant increase in the measured post-vaccination levels of the three antibodies among the enrolled volunteers compared to the basal pre-vaccination level and thus sputnik vaccine protects against SARS-CoV-2 infections.
- Open Access
- 2 July 2021
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 15 (3) , 1257-1265
Current Status and a Future Perspective of COVID-19 in Egypt: Egyptian Reference Laboratory Experience
Currently, the sole global concern is recurring waves of the COVID-19 virus that began in 2020 and is ongoing. This study aimed to compare the trends of COVID-19 infections in Egypt during the different waves. We calculated the COVID-19 positivity rate between March 2020 and the fourth week of April 2021 among those tested at the Reference Laboratory of the Egyptian University Hospitals. We then compared our results with those obtained from the WHO and the Egyptian Ministry of Health and Population websites. A dramatic increase in the positivity rate was observed during May and June 2020 (26.35% and 33.11%, respectively). This was followed by an abrupt reduction in July (11.7%), and flattening until a second increase was noted during November (9.6%), which reached its peak during December (17.8%). However, after the figures declined during January 2021, they began to rise again in February 2021 and continued to increase until the end of April 2021, simulating the first wave data. The analysis of the COVID-19 growth rate from April 1st to the 25th, 2021 revealed a slight downward trend in new cases. Data from both the WHO and the Egyptian Ministry of Health and Population websites showed similar patterns to our results. The third wave of COVID-19 started in Egypt. Analyzing future data can aid in forecasting the COVID-19 epidemic and allow us to use foresight to enact effective measures and strategies to keep this virus under control.
- 2 July 2021
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 15 (3) , 1257-1265
Open AccessCurrent Status and a Future Perspective of COVID-19 in Egypt: Egyptian Reference Laboratory Experience
Currently, the sole global concern is recurring waves of the COVID-19 virus that began in 2020 and is ongoing. This study aimed to compare the trends of COVID-19 infections in Egypt during the different waves. We calculated the COVID-19 positivity rate between March 2020 and the fourth week of April 2021 among those tested at the Reference Laboratory of the Egyptian University Hospitals. We then compared our results with those obtained from the WHO and the Egyptian Ministry of Health and Population websites. A dramatic increase in the positivity rate was observed during May and June 2020 (26.35% and 33.11%, respectively). This was followed by an abrupt reduction in July (11.7%), and flattening until a second increase was noted during November (9.6%), which reached its peak during December (17.8%). However, after the figures declined during January 2021, they began to rise again in February 2021 and continued to increase until the end of April 2021, simulating the first wave data. The analysis of the COVID-19 growth rate from April 1st to the 25th, 2021 revealed a slight downward trend in new cases. Data from both the WHO and the Egyptian Ministry of Health and Population websites showed similar patterns to our results. The third wave of COVID-19 started in Egypt. Analyzing future data can aid in forecasting the COVID-19 epidemic and allow us to use foresight to enact effective measures and strategies to keep this virus under control.